Marizyme Stock Buy Hold or Sell Recommendation
| MRZM Stock | USD 0.05 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Marizyme is 'Strong Sell'. The recommendation algorithm takes into account all of Marizyme's available fundamental, technical, and predictive indicators you will find on this site.
Check out Marizyme Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Marizyme and provide practical buy, sell, or hold advice based on investors' constraints. Marizyme. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as various price indices.
Marizyme |
Execute Marizyme Buy or Sell Advice
The Marizyme recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Marizyme. Macroaxis does not own or have any residual interests in Marizyme or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Marizyme's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Marizyme Trading Alerts and Improvement Suggestions
| Marizyme is way too risky over 90 days horizon | |
| Marizyme has some characteristics of a very speculative penny stock | |
| Marizyme appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 210.28 K. Net Loss for the year was (11 M) with profit before overhead, payroll, taxes, and interest of 129.93 K. | |
| Marizyme currently holds about 2.04 M in cash with (5.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. |
Marizyme Returns Distribution Density
The distribution of Marizyme's historical returns is an attempt to chart the uncertainty of Marizyme's future price movements. The chart of the probability distribution of Marizyme daily returns describes the distribution of returns around its average expected value. We use Marizyme price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Marizyme returns is essential to provide solid investment advice for Marizyme.
| Mean Return | 15.10 | Value At Risk | -33.33 | Potential Upside | 33.33 | Standard Deviation | 52.50 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Marizyme historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Marizyme Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Marizyme or Software sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Marizyme's price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Marizyme otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 15.77 | |
β | Beta against Dow Jones | -7.63 | |
σ | Overall volatility | 131.16 | |
Ir | Information ratio | 0.11 |
Marizyme Volatility Alert
Marizyme is showing large volatility of returns over the selected time horizon. Marizyme is a penny stock. Although Marizyme may be in fact a good investment, many penny otc stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Marizyme. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Marizyme instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Marizyme Fundamentals Vs Peers
Comparing Marizyme's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Marizyme's direct or indirect competition across all of the common fundamentals between Marizyme and the related equities. This way, we can detect undervalued stocks with similar characteristics as Marizyme or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Marizyme's fundamental indicators could also be used in its relative valuation, which is a method of valuing Marizyme by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Marizyme to competition |
| Fundamentals | Marizyme | Peer Average |
| Return On Equity | -0.5 | -0.31 |
| Return On Asset | -0.15 | -0.14 |
| Operating Margin | (180.85) % | (5.51) % |
| Current Valuation | 17.35 M | 16.62 B |
| Shares Outstanding | 10.13 M | 571.82 M |
| Shares Owned By Insiders | 2.04 % | 10.09 % |
| Price To Book | 0.37 X | 9.51 X |
| Price To Sales | 133.06 X | 11.42 X |
| Revenue | 210.28 K | 9.43 B |
| Gross Profit | 129.93 K | 27.38 B |
| EBITDA | (10.83 M) | 3.9 B |
| Net Income | (11 M) | 570.98 M |
| Cash And Equivalents | 2.04 M | 2.7 B |
| Cash Per Share | 0.05 X | 5.01 X |
| Total Debt | 495.32 K | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 1.74 X | 2.16 X |
| Book Value Per Share | 1.00 X | 1.93 K |
| Cash Flow From Operations | (5.79 M) | 971.22 M |
| Earnings Per Share | (0.39) X | 3.12 X |
| Number Of Employees | 11 | 18.84 K |
| Beta | 0.36 | -0.15 |
| Market Capitalization | 5.07 M | 19.03 B |
| Total Asset | 66 M | 29.47 B |
| Z Score | 6.0 | 8.72 |
| Net Asset | 66 M |
Marizyme Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Marizyme . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Marizyme Buy or Sell Advice
When is the right time to buy or sell Marizyme? Buying financial instruments such as Marizyme OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Marizyme in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Discretionary ETFs Thematic Idea Now
Consumer Discretionary ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.